Shares of iBio Inc. IBIO inched 0.37% higher to $2.72 Wednesday, on what proved to be an all-around mixed trading session for ...
Shares of iBio Inc. IBIO jumped 10.16% to $2.71 Tuesday, on what proved to be an all-around poor trading session for the ...
Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...
Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long ...
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the developme ...
Under this License Agreement, iBio will have exclusive rights, including sublicensing capabilities, for the development and commercialization of the product worldwide. In consideration for these ...
Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback